<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7295552\results\search\testTrace\results.xml">
  <result pre="article, we seek to collate and provide a summary of" exact="treatment" post="strategies for COVID-19 patients with a variable degree of"/>
  <result pre="in complicated cases of COVID-19. Coronavirus disease 2019 SARS-CoV-2 Pharmacological" exact="treatment" post="Medical management HIV Transplant ESKD Introduction Coronavirus disease 2019"/>
  <result pre="the COVID-19 pandemic are related to prevention, isolation, and supportive" exact="treatment" post="strategies. There are several ongoing clinical trials related to"/>
  <result pre="article, we seek to collate and provide a summary of" exact="treatment" post="strategies for COVID-19 patients with a variable degree of"/>
  <result pre="therapy must be used, patients should be in an airborne" exact="infection" post="isolation room (preferably negative pressure room), and any healthcare"/>
  <result pre="must be used, patients should be in an airborne infection" exact="isolation" post="room (preferably negative pressure room), and any healthcare worker"/>
  <result pre="to re-enter the room for 2 -3 h following nebulizer" exact="treatment" post="for risk of aerosolized transmission of the virus. Empiric"/>
  <result pre="of COVID-19 are challenging to distinguish from bacterial pneumonia. Empiric" exact="treatment" post="for bacterial pneumonia may also be reasonable in patients"/>
  <result pre="Empiric antibiotic therapy, if initiated, should be guided by microbial" exact="diagnosis" post="(e.g., sputum Gram stain and culture) and reevaluate the"/>
  <result pre="patients who are already on ACEI or ARB should continue" exact="treatment" post="with these agents if there is no other reason"/>
  <result pre="severe disease with respiratory viruses. However, no evidence routinely discontinuing" exact="treatment" post="is of any benefit. Therefore, the plan to discontinue"/>
  <result pre="on a case-by-case basis. COVID-19-negative patients with underlying conditions requiring" exact="treatment" post="with these agents should not be taken off suddenly,"/>
  <result pre="support the approach of continuing immunomodulatory therapy in patients without" exact="infection" post="[12]. Symptomatic management Fever is the most common symptom"/>
  <result pre="discussed earlier in this article. Management of respiratory failure Viral" exact="infection" post="causes inflammatory cytokine release and thereby edema in various"/>
  <result pre="from 15 days to 11 days in patients who received" exact="treatment" post="with it. It reduced the mortality from 11% to"/>
  <result pre="a history of diverticulosis. Baseline lipid panel and liver function" exact="testing" post="should also be done as these drugs might elevate"/>
  <result pre="effect in the in vitro model for MERS and SARS" exact="treatment" post="[31, 32]. Clinical trials so far have not managed"/>
  <result pre="[43]. Pros and cons Data obtained from the experiments involving" exact="treatment" post="of SARS-CoV and MERS-CoV and ISGâ€™s ability to disrupt"/>
  <result pre="pathway would be valuable for selecting IFN-beta as a potential" exact="treatment" post="option against SARS-CoV-2 [44, 45]. Type I (IFN-alpha and"/>
  <result pre="offer the only short-term strategy to confer immediate immunity to" exact="infection" post="susceptible patients [53]. In the absence of an effective"/>
  <result pre="susceptible patients [53]. In the absence of an effective specific" exact="treatment" post="for COVID-19, clinicians across the globe have used the"/>
  <result pre="or immediately life-threatening COVID-19 infections starting March 24, 2020. The" exact="treatment" post="with CP is considered experimental. It is important to"/>
  <result pre="coronavirus. Treatment with effective antiviral therapy is being sought; however," exact="treatment" post="of the systemic response to this viral infection is"/>
  <result pre="sought; however, treatment of the systemic response to this viral" exact="infection" post="is likely to be equally or more important. Overzealous"/>
  <result pre="to be equally or more important. Overzealous host response to" exact="infection" post="has been well described and involves a complex interaction"/>
  <result pre="performed with the close guidance of specialists, and risks of" exact="infection" post="or bleeding are minimized. So far, randomized trial data"/>
  <result pre="no major studies that have looked at clinical characteristics, antiretroviral" exact="treatment" post="(ART), and outcomes in people with COVID-19 co-infected with"/>
  <result pre="which may lead to disease flare and increased risk of" exact="infection" post="[71]. Some disease-modifying drugs which are commonly used to"/>
  <result pre="reactive hemophagocytic lymphohistiocytosis. However, conclusive evidence is lacking to guide" exact="treatment" post="decisions at this point. Case series from Italy by"/>
  <result pre="patients should continue to follow basic personal prevention procedures (e.g.," exact="social distancing," post="hand hygiene, and face mask use). At the same"/>
  <result pre="COVID-19. Although transplanted patients could be more susceptible to COVID-19" exact="infection" post="with atypical manifestations, the chronic use of immunosuppressive drugs"/>
  <result pre="A small case study by Li et al described COVID-19" exact="infection" post="in two solid-organ transplanted patients with variable symptoms who"/>
  <result pre="future will guide us with the management strategy of COVID-19" exact="infection" post="in solid-organ transplant patients and immunosuppression medications. Pregnancy and"/>
  <result pre="immunosuppression medications. Pregnancy and COVID-19 The comprehensive impact of COVID-19" exact="infection" post="on a pregnant woman is currently unclear. International Federation"/>
  <result pre="carefully managed with existing protocols as in routine pregnancy. COVID-19" exact="infection" post="itself is not an indication for delivery unless maternal"/>
  <result pre="and fetal condition. Currently, there is no evidence that COVID-19" exact="infection" post="is associated with fetal or placental complications or risk"/>
  <result pre="fetal or placental complications or risk of congenital malformation. The" exact="treatment" post="approach depending on the severity of COVID-19 infection is"/>
  <result pre="malformation. The treatment approach depending on the severity of COVID-19" exact="infection" post="is the same as for confirmed, suspected, and probable"/>
  <result pre="neonatologists, infectious disease specialists). Currently, there is no proven antiviral" exact="treatment" post="for COVID-19 patients, although antiretroviral drugs are being investigated"/>
  <result pre="the workup of pregnant women, if necessary, with suspected/probable/confirmed COVID-19" exact="infection" post="after discussing the risk and benefits with the patient."/>
  <result pre="dialysis ESKD patients likely are at significant risk of COVID-19" exact="infection" post="due to suppression of the immune system, and may"/>
  <result pre="the medical staff, and other patients are high due to" exact="treatment" post="in the same confined space. If infected, the intensity"/>
  <result pre="preventive measures are most critical to reduce the incidence of" exact="infection" post="in this vulnerable population. Strict protocols have been placed"/>
  <result pre="members have been particularly educated on guidelines to minimize the" exact="infection" post="risk and also to manage patients with signs of"/>
  <result pre="recommended guidelines to keep the dialysis units safe to continue" exact="treatment" post="at the dialysis unit itself without placing a burden"/>
  <result pre="questionnaire and temperature check has been implemented. Early recognition and" exact="isolation" post="of individuals with a respiratory infection, fever, cough, and"/>
  <result pre="mask usage policies have been implemented. Patients with confirmed COVID-19" exact="infection" post="are admitted to cohort dialysis units if they are"/>
  <result pre="moderate to severe symptoms are admitted to the hospital for" exact="isolation" post="and treatment [80, 81]. Patients receiving home dialysis (peritoneal"/>
  <result pre="severe symptoms are admitted to the hospital for isolation and" exact="treatment" post="[80, 81]. Patients receiving home dialysis (peritoneal and home"/>
  <result pre="including peritoneal dialysis (PD) patients, can also contract this viral" exact="infection" post="[82]. One case series from a HD center in"/>
  <result pre="case series from a HD center in Wuhan reported COVID-19" exact="infection" post="in 37 out of 230 HD patients (16.1%) and"/>
  <result pre="some degree and are preparing for the next wave of" exact="infection" post="to impact in the fall and winter of 2020."/>
  <result pre="and subsequent exponential growth in cases and mortality, have introduced" exact="physical distancing" post="measures. These measures are in the forms of â€œshutdownsâ€�"/>
  <result pre="consequences. Arguments are being made that the economic costs of" exact="social distancing" post="and stay-at-home are worse than the medical catastrophe. However,"/>
  <result pre="the medical catastrophe. However, in the absence of widely available" exact="testing" post="facilities, proven pharmacotherapeutics, and the introduction of an effective"/>
  <result pre="and the introduction of an effective vaccine, mere lifting of" exact="social distancing" post="restrictions will not be effective in ending the economic"/>
  <result pre="clinical trial involving IFN beta-1b, lopinavir/ritonavir, mainly used for the" exact="treatment" post="of HIV, ribavirin mainly used in combination with IFN"/>
  <result pre="HIV, ribavirin mainly used in combination with IFN for the" exact="treatment" post="of hepatitis C was tested in 86 patients for"/>
  <result pre="C was tested in 86 patients for 14 days for" exact="treatment" post="of COVID-19 in Hong Kong. The treatment group took"/>
  <result pre="14 days for treatment of COVID-19 in Hong Kong. The" exact="treatment" post="group took all the above medications while the control"/>
  <result pre="must prepare ourselves to sustain without a vaccine or effective" exact="treatment" post="for months. It is hard to estimate the costs"/>
  <result pre="and to avoid overwhelming the global healthcare infrastructures. Ramping up" exact="testing" post="for infection and antibody testing to assess the level"/>
  <result pre="avoid overwhelming the global healthcare infrastructures. Ramping up testing for" exact="infection" post="and antibody testing to assess the level of viral"/>
  <result pre="global healthcare infrastructures. Ramping up testing for infection and antibody" exact="testing" post="to assess the level of viral prevalence and immunity"/>
  <result pre="infection and antibody testing to assess the level of viral" exact="prevalence" post="and immunity So, resources can be allocated to high-risk"/>
  <result pre="to high-risk areas. Availability of fast, reliable point of care" exact="testing" post="capability would be able to identify and avoid transmission"/>
  <result pre="across the US healthcare systems. However, the availability of such" exact="testing" post="capacity may be implemented to screen the patients and"/>
  <result pre="screen the patients and surgical team preoperative to ascertain their" exact="infection" post="status and go ahead with even routine surgical procedures,"/>
  <result pre="summarized as follows. The first step is to keep the" exact="infection" post="rates low by imposing strict social distancing measures. Meanwhile,"/>
  <result pre="is to keep the infection rates low by imposing strict" exact="social distancing" post="measures. Meanwhile, we need to significantly ramp up testing"/>
  <result pre="social distancing measures. Meanwhile, we need to significantly ramp up" exact="testing" post="capabilities so that when we are ready to ease"/>
  <result pre="restrictions, anyone who needs a test can be tested for" exact="infection" post="as well as antibodies that would identify who are"/>
  <result pre="are immune. Second, when it is time to relax the" exact="social distancing," post="people with immunity could be provided with â€œimmunity passportsâ€�"/>
  <result pre="many states in the USA no longer has stay-at-home orders," exact="testing" post="capacity improved significantly but antibody testing remained scarce and"/>
  <result pre="longer has stay-at-home orders, testing capacity improved significantly but antibody" exact="testing" post="remained scarce and its interpretation - uncertain. Negative economic,"/>
  <result pre="the toll of the pandemic, we need to continue active" exact="contact tracing," post="isolation of positive patients, judicious use of emerging medical"/>
  <result pre="of the pandemic, we need to continue active contact tracing," exact="isolation" post="of positive patients, judicious use of emerging medical therapy,"/>
  <result pre="all relevant governmental agencies is of paramount importance in this" exact="testing" post="times. Clear, consistent and unbiased guidance from trusted authorities"/>
  <result pre="patients with COVID-19. https://www.who.int/publications-detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 5RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 6WuCChenXCaiYXiaJZhouXXuSHuangHet al.Risk factors associated with"/>
  <result pre="reportsJ Crit Care202058272810.1016/j.jcrc.2020.03.01132279018 22AsadaMYoshidaMSuzukiTHatachiYSasakiTYasudaHNakayamaKet al.Macrolide antibiotics inhibit respiratory syncytial virus" exact="infection" post="in human airway epithelial cellsAntiviral Res200983219120010.1016/j.antiviral.2009.05.00319463856 23RetallackHDi LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCMancia LeonWRet"/>
  <result pre="drug repurposingACS Infect Dis20151731732610.1021/acsinfecdis.5b0003027622822 25GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBet al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
  <result pre="trialInt J Antimicrob Agents202010594910.1016/j.ijantimicag.2020.10594932205204 26SimpsonTFKovacsRJStecklerECVentricular arrhythmia risk due to hydroxychloroquine-azithromycin" exact="treatment" post="for COVID-19Cardiology2020 27MagagnoliJNarendranSPereiraFCummingsTHardinJWSuttonSSAmbatiJOutcomes of hydroxychloroquine usage in United States"/>
  <result pre="blockade for cytokine stormImmunotherapy20168895997010.2217/imt-2016-002027381687 31ChuCMChengVCHungIFWongMMChanKHChanKSKaoRYet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax200459325225610.1136/thorax.2003.01265814985565 32de WildeAHJochmansDPosthumaCCZevenhoven-DobbeJCvan"/>
  <result pre="J Pharmacol20131701172210.1111/bph.1210723336732 37JafarzadehANematiMKhorramdelazadHHassanZMImmunomodulatory properties of cimetidine: Its therapeutic potentials for" exact="treatment" post="of immune-related diseasesInt Immunopharmacol20197015616610.1016/j.intimp.2019.02.02630802678 38Kapinska-MrowieckaMTurowskiG[Efficacy of cimetidine in treatment"/>
  <result pre="for treatment of immune-related diseasesInt Immunopharmacol20197015616610.1016/j.intimp.2019.02.02630802678 38Kapinska-MrowieckaMTurowskiG[Efficacy of cimetidine in" exact="treatment" post="of Herpes zoster in the first 5 days from"/>
  <result pre="herpes simplex virus infections in immunocompromised patientsClin Exp Dermatol198712532633110.1111/j.1365-2230.1987.tb02501.x3446417 40HarcourtJPWorleyGLeightonSECimetidine" exact="treatment" post="for recurrent respiratory papillomatosisInt J Pediatr Otorhinolaryngol199951210911310.1016/S0165-5876(99)00279-710619624 41ZhangWWangJSuBLiRDingZKangYWangBCimetidine augments"/>
  <result pre="44ChanJFYaoYYeungMLDengWBaoLJiaLLiFet al.Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
  <result pre="model of common marmosetJ Infect Dis2015212121904191310.1093/infdis/jiv39226198719 45StockmanLJBellamyRGarnerPSARS: systematic review of" exact="treatment" post="effectsPLoS Med200639e34310.1371/journal.pmed.003034316968120 46ChannappanavarRFehrARZhengJWohlford-LenaneCAbrahanteJEMackMSompallaeRet al.IFN-I response timing relative to virus"/>
  <result pre="al.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ Clin Invest20191303625363910.1172/JCI12636331355779 47LukeTCKilbaneEMJacksonJLHoffmanSLMeta-analysis: convalescent blood products for Spanish"/>
  <result pre="supply and transfusion transmitted infectionsBr J Haematol2012159213514210.1111/bjh.1203122924410 50HungIFToKKLeeCKLeeKLChanKYanWWLiuRet al.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
  <result pre="al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="53BlochEMShohamSCasadevallASachaisBSShazBWintersJLvan BuskirkCet al.Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J Clin Invest202010.1172/JCI13874532254064 54ShenCWangZZhaoFYangYLiJYuanJWangFet al.Treatment of 5 critically"/>
  <result pre="of cellular immunity and the inflammatory responseTrends Immunol200324947447810.1016/S1471-4906(03)00228-X12967670 59XuXHanMLiTSunWWangDFuBZhouYet al.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci"/>
  <result pre="al.High disease activity is associated with an increased risk of" exact="infection" post="in patients with rheumatoid arthritisAnn Rheum Dis201170578579110.1136/ard.2010.12863721288960 70MontiSBalduzziSDelvinoPBellisEQuadrelliVSMontecuccoCClinical course"/>
  <result pre="78ChenHGuoJWangCLuoFYuXZhangWLiJet al.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
 </snippets>
</snippetsTree>
